Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MDGN's Cash to Debt is ranked higher than
82% of the 1270 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. MDGN: No Debt )
MDGN' s 10-Year Cash to Debt Range
Min: 0.46   Max: No Debt
Current: No Debt

Interest Coverage No Debt
MDGN's Interest Coverage is ranked higher than
94% of the 575 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MDGN: No Debt )
MDGN' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: 20.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -102.76
MDGN's ROE (%) is ranked higher than
59% of the 1154 Companies
in the Global Biotechnology industry.

( Industry Median: -34.19 vs. MDGN: -102.76 )
MDGN' s 10-Year ROE (%) Range
Min: -611.28   Max: -76.67
Current: -102.76

-611.28
-76.67
ROA (%) -82.63
MDGN's ROA (%) is ranked higher than
58% of the 1274 Companies
in the Global Biotechnology industry.

( Industry Median: -27.54 vs. MDGN: -82.63 )
MDGN' s 10-Year ROA (%) Range
Min: -484.61   Max: -64.26
Current: -82.63

-484.61
-64.26
ROC (Joel Greenblatt) (%) -4373.90
MDGN's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1243 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. MDGN: -4373.90 )
MDGN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5026.23   Max: -1228.57
Current: -4373.9

-5026.23
-1228.57
EBITDA Growth (3Y)(%) 1.80
MDGN's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 697 Companies
in the Global Biotechnology industry.

( Industry Median: -4.50 vs. MDGN: 1.80 )
MDGN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -17.5   Max: 184.4
Current: 1.8

-17.5
184.4
» MDGN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

MDGN Guru Trades in

MDGN Guru Trades in

Q2 2013

MDGN Guru Trades in Q2 2013

Jim Simons 15,300 sh (-41.83%)
» More
Q3 2013

MDGN Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.99
MDGN's P/B is ranked higher than
75% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 6.64 vs. MDGN: 4.99 )
MDGN' s 10-Year P/B Range
Min: 0   Max: 30.2
Current: 4.99

0
30.2
EV-to-EBIT -8.37
MDGN's EV-to-EBIT is ranked higher than
87% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. MDGN: -8.37 )
MDGN' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -8.37

Current Ratio 9.24
MDGN's Current Ratio is ranked higher than
86% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. MDGN: 9.24 )
MDGN' s 10-Year Current Ratio Range
Min: 0.14   Max: 9.24
Current: 9.24

0.14
9.24
Quick Ratio 9.24
MDGN's Quick Ratio is ranked higher than
86% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. MDGN: 9.24 )
MDGN' s 10-Year Quick Ratio Range
Min: 0.14   Max: 9.24
Current: 9.24

0.14
9.24

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.16
MDGN's Price/Net Cash is ranked higher than
89% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 55.07 vs. MDGN: 5.16 )
MDGN' s 10-Year Price/Net Cash Range
Min: 3.33   Max: 148.8
Current: 5.16

3.33
148.8
Price/Net Current Asset Value 5.13
MDGN's Price/Net Current Asset Value is ranked higher than
88% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 35.37 vs. MDGN: 5.13 )
MDGN' s 10-Year Price/Net Current Asset Value Range
Min: 3.31   Max: 106.29
Current: 5.13

3.31
106.29
Price/Tangible Book 4.99
MDGN's Price/Tangible Book is ranked higher than
81% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 10.00 vs. MDGN: 4.99 )
MDGN' s 10-Year Price/Tangible Book Range
Min: 3.22   Max: 46.5
Current: 4.99

3.22
46.5
Earnings Yield (Greenblatt) -11.90
MDGN's Earnings Yield (Greenblatt) is ranked higher than
58% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. MDGN: -11.90 )
MDGN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -26.3   Max: 0
Current: -11.9

-26.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MEDU.UK, MEDG.UK,
Medgenics Inc was incorporated on 27th January 2000 in Delaware. It is a medical technology and therapeutics company. The Company and its subsidiary are engaged in the research and development of products in the field of biotechnology and associated medical equipment. The Company has developed a novel technology for the manufacture and delivery of therapeutic proteins continuously in patients using their own tissue. The company has also developed an Interferon Alpha secreting Biopump for the treatment of viral Hepatitis. The Company's Biopump Platform Technology converts a small piece of the patient's own dermal skin tissue into a protein. Its proprietary device, the DermaVac, is used to extract a small piece of tissue via a form of needle biopsy from the skin's lower level - the dermis - of patient under local anesthesia. Its EPODURE Biopump is designed to provide a safer, more reliable, and more cost-effective anemia therapy. The Company face competition within protein/peptide therapeutics, directly from established competitors using alternative protein manufacturing and delivery methods for EPO and in many orphan and rare disease areas respectively. The Company's production, distribution, and marketing of products employing its technology, and its development activities, are subject to extensive governmental regulation in the United States and in other countries. In the United States, its products are regulated as biologics and medical devices and are subject to the Federal Food, Drug, and Cosmetic Act, as amended, and the regulations of the FDA, as well as to other federal, state, and local statutes and regulations.
» More Articles for MDGN

Headlines

Articles On GuruFocus.com
Sleepy Sector Wakes Up - Billionaires Hold Biotechs in 52-week Low Sep 03 2013 

More From Other Websites
MEDGENICS, INC. Financials Feb 20 2015
10-K for Medgenics, Inc. Feb 15 2015
Medgenics reports 4Q loss Feb 13 2015
Medgenics reports 4Q loss Feb 13 2015
Medgenics Inc Earnings Call scheduled for 8:30 am ET today Feb 13 2015
Medgenics Reports Fourth Quarter and Full Year 2014 Financial Results Feb 13 2015
MEDGENICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD... Feb 13 2015
MEDGENICS, INC. Files SEC form 10-K, Annual Report Feb 13 2015
Medgenics Reports Fourth Quarter and Full Year 2014 Financial Results Feb 13 2015
Q4 2014 Medgenics Inc Earnings Release - Before Market Open Feb 13 2015
Medgenics to Host Conference Call to Announce Fourth Quarter and Full Year 2014 Results on February... Jan 30 2015
Medgenics to Host Conference Call to Announce Fourth Quarter and Full Year 2014 Results on February... Jan 30 2015
MDGN: Positive MDGN-201 Data Through 7 Months Jan 16 2015
Medgenics to Present at Biotech Showcase 2015 Conference Jan 08 2015
Medgenics to Present at Biotech Showcase 2015 Conference Jan 08 2015
Medgenics Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to... Dec 01 2014
Medgenics Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to... Dec 01 2014
MEDGENICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements... Dec 01 2014
Medgenics Prices Public Offering of Common Stock Nov 25 2014
Medgenics Announces Public Offering of Common Stock Nov 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK